Currently Viewing:
COA Community Oncology Conference 2019
Currently Reading
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr Basit Chaudhry on the Importance of Taking Into Account Differences Among OCM Practices

Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.


Under the Oncology Care Model (OCM), there's a wide range of practice sizes, creating challenges for evaluation, said Basit Chaudhry, MD, PhD, founder of Tuple Health.

Transcript

Why is it important for OCM evaluation to take into consideration differences among participating practices?

One of the things that’s very different about OCM, in part because of the selection criteria for entering the model, it was really oriented around practices in the community or outpatient setting. What this has done is the participants inside of OCM, there’s often a scale order of difference in how large they are. So, this is a kind of interesting thing. In other CMMI [Center for Medicare and Medicaid Innovation] models, you don’t have this kind of massive difference in scale. There’s, I believe, a practice that’s a 1-physician practice in OCM and there’s a 300-physician practice in OCM. This creates real challenges on the evaluation, because if you’re trying to essentially match practices as comparisons, it becomes very difficult because of the very skewed distribution.

The evaluation of this model is also particularly important because due to the complexity of cancer care on the model itself, there have been a number of methodologic changes that have been made along the way. So, in a way, it’s a moving target over what OCM performance is, so the evaluators I think, have a very important job to think about how do we really assess what the impact of this payment model has been. That’s especially important in this model, and it’s key to all CMMI models, but it’s especially important in OCM. There’s a lot of decisions that will need to be made on how the evaluation will be done, so it will be interesting to see how that works.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up